alexa Infliximab-induced psoriasis in children with inflammatory bowel disease.
Dermatology

Dermatology

Journal of Clinical & Experimental Dermatology Research

Author(s): Hiremath G, Duffy L, Leibowitz I

Abstract Share this page

Abstract Infliximab is frequently used to treat both inflammatory bowel disease (IBD) and psoriasis. We reviewed the medical records of 73 children with IBD receiving infliximab therapy and identified 6 (8\%) cases of infliximab-induced psoriasis. Five (83\%) had Crohn disease and 4 (67\%) were girls. The psoriatic lesions appeared on the face (n = 5; 83\%) and perineum (n = 1; 17\%). A median of 13 doses were administered during a median duration of 21 months. All of the patients were continued on infliximab to maintain clinical remission of IBD. Educating children with IBD and their caregivers about this paradoxical phenomenon and periodic dermatology evaluation may promote patient care. This article was published in J Pediatr Gastroenterol Nutr and referenced in Journal of Clinical & Experimental Dermatology Research

Relevant Expert PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords